Is CLOV a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Medicare Advantage membership growth, with 2026 revenue guidance at Guided to the multi-billion-dollar range (roughly $2.8B to $2.9B midpoint framing; approximate). The bear case rests on the dominant risk is that Clover is a small insurer competing against giants like UnitedHealth, Humana, CVS/Aetna, and Centene, which have far greater scale, capital, and provider leverage. Analysts covering it are spread from $3.50 to $5.50, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The dominant risk is that Clover is a small insurer competing against giants like UnitedHealth, Humana, CVS/Aetna, and Centene, which have far greater scale, capital, and provider leverage. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $3.50, -16.9% from the $4.21 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Medicare Advantage membership growth. Clover has been growing membership far faster than the broader Medicare Advantage market, with roughly 50% year-over-year growth into the 2026 plan year and guidance for continued expansion. The most optimistic analyst target on CLOV is $5.50, +30.6% from the $4.21 price. That figure is only reachable if this thesis works close to its best case.

The dominant risk is that Clover is a small insurer competing against giants like UnitedHealth, Humana, CVS/Aetna, and Centene, which have far greater scale, capital, and provider leverage. Medicare Advantage economics are highly sensitive to the medical-cost ratio: if members use more care than priced, a fast-growing book can swing back to losses quickly. The business is heavily dependent on CMS policy, reimbursement rates, risk-adjustment rules, and Star Ratings, all of which are outside the company's control and can change materially between plan years. Profitability is recent and not yet long-proven, so the turn could reverse if growth outpaces cost discipline. Insurtech peers such as Alignment Healthcare, Oscar Health, and Devoted Health add competitive pressure, and the stock has historically been volatile with elevated retail and short-interest attention. The most pessimistic published target is $3.50, -16.9% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Clover Health Investments, Corp.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Medicare Advantage membership growth) stalling in the reported numbers rather than in the narrative, the risk above (the dominant risk is that Clover is a small insurer competing against giants like UnitedHealth, Humana, CVS/Aetna, and Centene, which have far greater scale, capital, and provider leverage) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is fast Medicare Advantage membership growth, a recent turn to profitability, a favorable 2026 Star Rating, and the Clover Assistant technology differentiator. The bear case is that Clover is a small insurer competing against giants, its profitability is new and unproven over time, and results are highly sensitive to medical costs and CMS policy. Weigh both against your own portfolio.

Clover Health is a healthcare-technology company that sells Medicare Advantage plans, mostly wide-network PPO plans, to US seniors. It pairs those plans with Clover Assistant, a proprietary software platform that gives physicians data-driven insights at the point of care to catch conditions earlier and manage costs. Its revenue comes primarily from the premiums CMS pays for its Medicare Advantage members.

Clover spent years unprofitable, as many fast-growing insurtechs do, but it guided to positive adjusted EBITDA and its first full year of GAAP net income profitability in 2026 and reported positive results early in the year. That turn is recent and not yet proven over multiple years, so profitability could still be pressured if medical costs rise faster than expected. Check the latest quarter for current status.